BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Rare cases of chronic myelogenous leukemia (CML) express high levels of alternatively spliced BCR-ABL mRNA with a 35-bp insertion (35INS) between ABL kinase domain exons 8 and 9. This insertion results in a frameshift leading to the addition of 10 residues and truncation of 653 residues due to early termination. Sensitive PCR-based testing showed that 32 of 52 (62%) imatinib-resistant CML patients in chronic phase and 8 of 38 (21%) in accelerated or blast crisis expressed varying levels of the alternatively spliced BCR-ABL mRNA. A three-dimensional structural model of the 35INS ABL kinase domain complexed with imatinib was built using homology modeling, followed by molecular dynamics simulations. Simulation results showed that the new residues cause a significant global conformational change, altering imatinib binding in a way similar to that of the T315I mutation and, therefore, providing resistance to imatinib that depends on the level of expression. [Mol Cancer Ther 2008;7(12):3834–41]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“The T315I mutation (18, 19) and some mutations affecting the socalled P-loop of BCR-ABL confer a greater level of resistance to imatinib (16, 17, 20) and even the new tyrosine kinase inhibitors that are currently used and tested in these patients (12, 21).”
Background
Cited by
Chronic myeloid leukemia: mechanisms of blastic transformation
Perrotti, D., Jamieson, C., Goldman, J., & Skorski, T. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41246 · Cited by 397
Cross, N. C. P., Ernst, T., Branford, S., Cayuela, J.-M., Deininger, M., Fabarius, A., Kim, D. D. H., Machova Polakova, K., Radich, J. P., Hehlmann, R., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02048-y · Cited by 120
“The so called ‘ 35ins ’ variant for example, is the retention of 35 intronic nucleotides at the junction between exon 8 and 9 [150 – 152].”
BackgroundGandhi, A. K., Mendy, D., Waldman, M., Chen, G., Rychak, E., Miller, K., Gaidarova, S., Ren, Y., Wang, M., Breider, M., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12622 · Cited by 106
“More importantly, the study demonstrated that alternative splicing occurs in a significant proportion of MM patients and thus the process may be relevant from both disease-biology and drug-development perspectives (Moalli et al, 1993; Bakkour et al, 2007; Lee et al, 2008).”
BackgroundBerman, E., Jhanwar, S., Hedvat, C., Arcila, M. E., Wahab, O. A., Levine, R., Maloy, M., Ma, W., & Albitar, M. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.08.006 · Cited by 41
Self-citationGaillard, J.-B., Arnould, C., Bravo, S., Donadio, D., Exbrayat, C., Jourdan, E., Reboul, D., Chiesa, J., & Lavabre-Bertrand, T. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0595 · Cited by 23
Metadata
- Authors
- Lee, T.-S., Ma, W., Zhang, X., Giles, F., Cortes, J., Kantarjian, H., & Albitar, M.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2008-12-01
- Volume
- 7
- Issue
- 12
- Pages
- 3834-3841
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2161484950
- Cited by
- 65
- References
- 1
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. https://app.cochat.ai/papers/10.1158/1535-7163.mct-08-0482
- The paper
- Lee, T.-S., Ma, W., Zhang, X., Giles, F., Cortes, J., Kantarjian, H., & Albitar, M. (2008). BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-08-0482
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.